Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut health under the microscope: new study targets hidden danger in ICU blood cancer patients

NCT ID NCT07022548

Knowledge-focused Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at how common gut inflammation and leaky gut are in 80 adults with blood cancer who were in intensive care for sepsis or septic shock. Researchers measured two markers—calprotectin in stool and zonulin in blood—to better understand intestinal dysfunction. The goal was to gather knowledge, not to test a treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better identify and manage gut problems in blood cancer patients with severe infections in intensive care.
What could go wrong
This is a small, completed observational study that only measures markers, not a treatment trial. The findings may not apply to all patients or lead to direct changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

80 people

The number who actually took part.

Started

Nov 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

40 patients with malignant haemopathy admitted for sepsis or septic shock in intensive care and a control population of 40 patients admitted to intensive care for sepsis or septic shock

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Population with hematologic malignancy * Patients over 18 years of age * Suffering from hematologic malignancy * Admitted to intensive care for sepsis or septic shock according to sepsis definition 3: * Sepsis: organ dysfunction (SOFA \> or = 2) related to a host response to infection * Septic shock: sepsis with acute circulatory failure and metabolic abnormalities (serum lactate \> 2 mmol/L) and vasopressors * Patients who have read and understood the information letter and do not object to participating in the study * Affiliated with or beneficiary of a social security scheme. Control population \- Patient aged over 18 Admitted to intensive care for sepsis or septic shock according to the sepsis definition 3: * Sepsis: organ dysfunction (SOFA \> or = 2) related to a host response to infection * Septic shock: sepsis with acute circulatory failure and metabolic abnormalities (serum lactate \> 2 mmol/L) and vasopressors * Patient who has read and understood the information letter and does not object to participating in the study * Member of or beneficiary of a social security scheme Exclusion Criteria: For the control group and those with hematologic malignancies: * Patient refusal * Pregnant, parturient, or breastfeeding woman * Person deprived of liberty by an administrative or judicial decision or person placed under judicial protection/guardianship or curatorship * Person who does not understand or speak French * Moribund * Limitations of active therapies (LATA) established upon admission * Hospitalization in intensive care \> 72 hours

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematologic malignancy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm infectious disease with sepsis Sepsis toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intestinal inflammation

Contacts and locations

Locations

  • Médecine Intensive Réanimation

    Rouen, 76031, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.